Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.43 |
| ▸ | PRF1 | P14222 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7284347 | 0.83 | BRD4 (0.49) | BRD4L3MBTL1NR4A2PRF1KMT2A | |
| SCHEMBL29263733 | 0.83 | NR4A2 (0.64) | BRD4NR4A2KMT2AMEN1ALDH1A1 | |
| SCHEMBL20923879 | 0.82 | KCNH2 (0.42) | BRD4L3MBTL1KMT2AMEN1POLB | |
| SCHEMBL16653430 | 0.80 | CNR2 (0.46) | NR4A2KMT2AMEN1POLBKCNH2 | |
| SCHEMBL9572754 | 0.80 | KCNH2 (0.59) | BRD4L3MBTL1NR4A2PRF1KMT2A | |
| SCHEMBL7275971 | 0.80 | KDM4E (0.55) | BRD4L3MBTL1NR4A2PRF1KMT2A | |
| SCHEMBL18539353 | 0.80 | NR4A2 (0.40) | NR4A2KMT2AMEN1POLBCHEK1 | |
| SCHEMBL6001725 | 0.79 | BAZ2B (0.48) | NR4A2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3931725 | 0.79 | KDM4E (0.50) | BRD4L3MBTL1NR4A2PRF1KMT2A | |
| SCHEMBL13392410 | 0.78 | BRD4 (0.44) | BRD4L3MBTL1NR4A2PRF1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2010054107-A2 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | PRINCIPIA BIOPHARMA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-6951881-B2 | (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-10-04 | — | — | US | disclosed |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028981-A1 | Kinase Knockdown Via Electrophilically Enhanced Inhibitors | MAP3K20, MAP3K6, MAP3K19 | BRD4 439/4885L3MBTL1 560/4885NR4A2 2401/4885 |
| US-20030232843-A1 | (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | BRD4 628/4885L3MBTL1 3356/4885NR4A2 662/4885 |
| US-20100113520-A1 | KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS | MAP3K20, MAP3K6, MAP3K19 | BRD4 439/4885L3MBTL1 560/4885NR4A2 2401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.